Allosteric Modulation of Metabotropic Glutamate Receptors

Advances in Pharmacology

Volumn 62, Issue , 2011, Pages 37-77

  Sheffler, Douglas J ^a   Gregory, Karen J ^a,b   Rook, Jerri M ^a   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Allosteric modulator; G protein coupled receptors; Metabotropic glutamate receptor; NAM; Neuromodulation; PAM

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ADX 47273; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BAY 367620; CHOLINESTERASE INHIBITOR; CINACALCET; GLUTAMIC ACID; JNJ 16259685; LY 2389575; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 6; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR 8; NEUROLEPTIC AGENT; PHENCYCLIDINE; RO 677476; UNCLASSIFIED DRUG; UNINDEXED DRUG; VU 0155141; VU 0285683; VU 0360172; VU 29; VU 48; VU 71; YM 298198;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ANXIETY; ANXIETY DISORDER; BOOK; COGNITION; COGNITIVE DEFECT; CONFORMATIONAL TRANSITION; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FRAGILE X SYNDROME; HUMAN; HYPERPARATHYROIDISM; MEMORY DISORDER; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; TRANQUILIZING ACTIVITY; WORKING MEMORY;

EID: 80052664751     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385952-5.00010-5     Document Type: Chapter

References (243)

1. Adewale A.S., Platt D.M., Spealman R.D. Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics 2006, 318(2):922-931.
2. Aiba A., Chen C., Herrup K., Rosenmund C., Stevens C.F., Tonegawa S. Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell 1994, 79(2):365-375.
3. Aiba A., Kano M., Chen C., Stanton M.E., Fox G.D., Herrup K., et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 1994, 79(2):377-388.
4. Alexander G.M., Godwin D.W. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Research 2006, 71(1):1-22.
5. Annoura H., Fukunaga A., Uesugi M., Tatsuoka T., Horikawa Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorganic & Medicinal Chemistry Letters 1996, 6(7):763-766.
6. Anwyl R. Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Brain Research. Brain Research Reviews 1999, 29(1):83-120.
7. Ayala J.E., Chen Y., Banko J.L., Sheffler D.J., Williams R., Telk A.N., et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009, 34(9):2057-2071.
8. Ayala J.E., Niswender C.M., Luo Q., Banko J.L., Conn P.J. Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacology 2008, 54(5):804-814.
9. Backstrom P., Hyytia P. Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG. European Journal of Pharmacology 2005, 528(1-3):110-118.
10. Ballesteros J., Palczewski K. G protein-coupled receptor drug discovery: Implications from the crystal structure of rhodopsin. Current Opinion in Drug Discovery & Development 2001, 4(5):561-574.
11. Baptista M.A., Martin-Fardon R., Weiss F. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: Comparison between cocaine and a potent conventional reinforcer. The Journal of Neuroscience 2004, 24(20):4723-4727.
12. Battaglia G., Busceti C.L., Molinaro G., Biagioni F., Traficante A., Nicoletti F., et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. The Journal of Neuroscience 2006, 26(27):7222-7229.
13. Bear M.F. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes, Brain, and Behavior 2005, 4(6):393-398.
14. Bellone C., Luscher C., Mameli M. Mechanisms of synaptic depression triggered by metabotropic glutamate receptors. Cellular and Molecular Life Sciences 2008, 65(18):2913-2923.
15. Beqollari D., Kammermeier P.J. The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors. European Journal of Pharmacology 2008, 589(1-3):49-52.
16. Bessis A.S., Bertrand H.O., Galvez T., De Colle C., Pin J.P., Acher F. Three-dimensional model of the extracellular domain of the type 4a metabotropic glutamate receptor: New insights into the activation process. Protein Science 2000, 9(11):2200-2209.
17. Bessis A.S., Rondard P., Gaven F., Brabet I., Triballeau N., Prezeau L., et al. Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(17):11097-11102.
18. Bhave G., Nadin B.M., Brasier D.J., Glauner K.S., Shah R.D., Heinemann S.F., et al. Membrane topology of a metabotropic glutamate receptor. The Journal of Biological Chemistry 2003, 278(32):30294-30301.
19. Blednov Y.A., Walker D., Osterndorf-Kahanek E., Harris R.A. Mice lacking metabotropic glutamate receptor 4 do not show the motor stimulatory effect of ethanol. Alcohol 2004, 34(2-3):251-259.
20. Bossert J.M., Busch R.F., Gray S.M. The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking. Neuroreport 2005, 16(9):1013-1016.
21. Bossert J.M., Gray S.M., Lu L., Shaham Y. Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology 2006, 31(10):2197-2209.
22. Bradbury M.J., Campbell U., Giracello D., Chapman D., King C., Tehrani L., et al. Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. The Journal of Pharmacology and Experimental Therapeutics 2005, 313(1):395-402.
23. Bradley S.J., Watson J.M., Challiss R.A. Effects of positive allosteric modulators on single-cell oscillatory Ca2 plus signaling initiated by the type 5 metabotropic glutamate receptor. Molecular Pharmacology 2009, 76(6):1302-1313.
24. Brauner-Osborne H., Jensen A.A., Krogsgaard-Larsen P. Interaction of CPCCOEt with a chimeric mGlu1b and calcium sensing receptor. Neuroreport 1999, 10(18):3923-3925.
25. Brodkin J., Bradbury M., Busse C., Warren N., Bristow L.J., Varney M.A. Reduced stress-induced hyperthermia in mGluR5 knockout mice. The European Journal of Neuroscience 2002, 16(11):2241-2244.
26. Brody S.A., Conquet F., Geyer M.A. Disruption of prepulse inhibition in mice lacking mGluR1. The European Journal of Neuroscience 2003, 18(12):3361-3366.
27. Brody S.A., Conquet F., Geyer M.A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl) 2004, 172(2):187-195.
28. Brody S.A., Dulawa S.C., Conquet F., Geyer M.A. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Molecular Psychiatry 2004, 9(1):35-41.
29. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. The Journal of Neuroscience 1998, 18(23):9594-9600.
30. Bruno V., Sureda F.X., Storto M., Casabona G., Caruso A., Knopfel T., et al. The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. The Journal of Neuroscience 1997, 17(6):1891-1897.
31. Bushell T.J., Sansig G., Collett V.J., van der Putten H., Collingridge G.L. Altered short-term synaptic plasticity in mice lacking the metabotropic glutamate receptor mGlu7. ScientificWorldJournal 2002, 2:730-737.
32. Callaerts-Vegh Z., Beckers T., Ball S.M., Baeyens F., Callaerts P.F., Cryan J.F., et al. Concomitant deficits in working memory and fear extinction are functionally dissociated from reduced anxiety in metabotropic glutamate receptor 7-deficient mice. The Journal of Neuroscience 2006, 26(24):6573-6582.
33. Caraci F., Molinaro G., Battaglia G., Giuffrida M.L., Riozzi B., Traficante A., et al. Targeting group-II metabotropic glutamate receptors for the treatment of psychosis associated with Alzheimer's disease: Selective activation of mGlu2 receptors amplifies {beta}-amyloid toxicity in cultured neurons whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Molecular Pharmacology 2010, 79(3):618-626.
34. Carroll F.Y., Stolle A., Beart P.M., Voerste A., Brabet I., Mauler F., et al. BAY36-7620: A potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Molecular Pharmacology 2001, 59(5):965-973.
35. Cartmell J., Monn J.A., Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. The Journal of Pharmacology and Experimental Therapeutics 1999, 291(1):161-170.
36. Ceccarelli S.M., Jaeschke G., Buettelmann B., Huwyler J., Kolczewski S., Peters J.U., et al. Rational design, synthesis, and structure-activity relationship of benzoxazolones: New potent mglu5 receptor antagonists based on the fenobam structure. Bioorganic & Medicinal Chemistry Letters 2007, 17(5):1302-1306.
37. Chavez-Noriega L.E., Marino M.J., Schaffhauser H., Campbell U.C., Conn P.J. Novel potential therapeutics for schizophrenia: Focus on the modulation of metabotropic glutamate receptor function. Current Neuropharmacology 2005, 3(1):9-34.
38. Chen Y., Goudet C., Pin J.P., Conn P.J. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hy droxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Molecular Pharmacology 2008, 73(3):909-918.
39. Chen Y., Nong Y., Goudet C., Hemstapat K., de Paulis T., Pin J.P., et al. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Molecular Pharmacology 2007, 71(5):1389-1398.
40. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318(5854):1258-1265.
41. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nature Neuroscience 2001, 4(9):873-874.
42. Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330(6007):1091-1095.
43. Conn P.J., Battaglia G., Marino M.J., Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature Reviews. Neuroscience 2005, 6(10):787-798.
44. Conn P.J., Lindsley C.W., Jones C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacological Sciences 2009, 30(1):25-31.
45. Corti C., Battaglia G., Molinaro G., Riozzi B., Pittaluga A., Corsi M., et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. The Journal of Neuroscience 2007, 27(31):8297-8308.
46. Cosford N.D., Roppe J., Tehrani L., Schweiger E.J., Seiders T.J., Chaudary A., et al. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: Potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorganic & Medicinal Chemistry Letters 2003, 13(3):351-354.
47. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. Journal of Medicinal Chemistry 2003, 46(2):204-206.
48. Cryan J.F., Kelly P.H., Neijt H.C., Sansig G., Flor P.J., van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. The European Journal of Neuroscience 2003, 17(11):2409-2417.
49. de Paulis T., Hemstapat K., Chen Y., Zhang Y., Saleh S., Alagille D., et al. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. Journal of Medicinal Chemistry 2006, 49(11):3332-3344.
50. Dhanya R.P., Sidique S., Sheffler D.J., Nickols H.H., Herath A., Yang L., et al. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. Journal of Medicinal Chemistry 2011, 54(1):342-353.
51. Dhingra A., Lyubarsky A., Jiang M., Pugh E.N., Birnbaumer L., Sterling P., et al. The light response of ON bipolar neurons requires G[alpha]o. The Journal of Neuroscience 2000, 20(24):9053-9058.
52. Doherty J.J., Alagarsamy S., Bough K.J., Conn P.J., Dingledine R., Mott D.D. Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus. The Journal of Physiology 2004, 561(Pt 2):395-401.
53. Dolen G., Carpenter R.L., Ocain T.D., Bear M.F. Mechanism-based approaches to treating fragile X. Pharmacology & Therapeutics 2010, 127(1):78-93.
54. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial Agents and Chemotherapy 2005, 49(11):4721-4732.
55. Dunnett S.B. The role and repair of forebrain cholinergic systems in short-term memory. Studies using the delayed matching-to-position task in rats. Advances in Neurology 1993, 59:53-65.
56. Duvoisin R.M., Zhang C., Pfankuch T.F., O'Connor H., Gayet-Primo J., Quraishi S., et al. Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8. The European Journal of Neuroscience 2005, 22(2):425-436.
57. Ehlert F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Molecular Pharmacology 1988, 33(2):187-194.
58. Fell M.J., Katner J.S., Johnson B.G., Khilevich A., Schkeryantz J.M., Perry K.W., et al. Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge. Neuropharmacology 2010, 58(3):632-639.
59. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). The Journal of Pharmacology and Experimental Therapeutics 2008, 326(1):209-217.
60. Fell M.J., Witkin J.M., Falcone J.F., Katner J.S., Perry K.W., Hart J., et al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)- 1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: In vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. The Journal of Pharmacology and Experimental Therapeutics 2011, 336(1):165-177.
61. Fendt M., Schmid S., Thakker D.R., Jacobson L.H., Yamamoto R., Mitsukawa K., et al. mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Molecular Psychiatry 2008, 13(10):970-979.
62. Ferraguti F., Shigemoto R. Metabotropic glutamate receptors. Cell and Tissue Research 2006, 326(2):483-504.
63. Galandrin S., Oligny-Longpre G., Bouvier M. The evasive nature of drug efficacy: Implications for drug discovery. Trends in Pharmacological Sciences 2007, 28(8):423-430.
64. Galici R., Echemendia N.G., Rodriguez A.L., Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. The Journal of Pharmacology and Experimental Therapeutics 2005, 315(3):1181-1187.
65. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. The Journal of Pharmacology and Experimental Therapeutics 2006, 318(1):173-185.
66. Gasparini F., Floersheim P., Flor P.J., Heinrich M., Inderbitzin W., Ott D., et al. Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. Farmaco 2001, 56(1-2):95-99.
67. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38(10):1493-1503.
68. Gerlai R., Roder J.C., Hampson D.R. Altered spatial learning and memory in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. Behavioral Neuroscience 1998, 112(3):525-532.
69. Gil-Sanz C., Delgado-Garcia J.M., Fairen A., Gruart A. Involvement of the mGluR1 receptor in hippocampal synaptic plasticity and associative learning in behaving mice. Cerebral Cortex 2008, 18(7):1653-1663.
70. Goddyn H., Callaerts-Vegh Z., Stroobants S., Dirikx T., Vansteenwegen D., Hermans D., et al. Deficits in acquisition and extinction of conditioned responses in mGluR7 knockout mice. Neurobiology of Learning and Memory 2008, 90(1):103-111.
71. Goudet C., Gaven F., Kniazeff J., Vol C., Liu J., Cohen-Gonsaud M., et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(1):378-383.
72. Goudet C., Magnaghi V., Landry M., Nagy F., Gereau R.W.t., Pin J.P. Metabotropic receptors for glutamate and GABA in pain. Brain Research Reviews 2009, 1(1):43-56.
73. Govek S.P., Bonnefous C., Hutchinson J.H., Kamenecka T., McQuiston J., Pracitto R., et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophrenia. Bioorganic & Medicinal Chemistry Letters 2005, 15(18):4068-4072.
74. Gray L., van den Buuse M., Scarr E., Dean B., Hannan A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: Association with N-methyl-D-aspartic acid receptor up-regulation. The International Journal of Neuropsychopharmacology 2009, 12(1):45-60.
75. Gregory K.J., Dong E.N., Meiler J., Conn P.J. Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential. Neuropharmacology 2010, 60(1):66-81.
76. Hackler E.A., Byun N.E., Jones C.K., Williams J.M., Baheza R., Sengupta S., et al. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 2010, 168(1):209-218.
77. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Molecular Pharmacology 2000, 58(6):1412-1423.
78. Harrison P.J., Lyon L., Sartorius L.J., Burnet P.W., Lane T.A. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): Expression, function and involvement in schizophrenia. Journal of Psychopharmacology 2008, 22(3):308-322.
79. Hemstapat K., Da Costa H., Nong Y., Brady A.E., Luo Q., Niswender C.M., et al. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. The Journal of Pharmacology and Experimental Therapeutics 2007, 322(1):254-264.
80. Hemstapat K., de Paulis T., Chen Y., Brady A.E., Grover V.K., Alagille D., et al. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Molecular Pharmacology 2006, 70(2):616-626.
81. Heresco-Levy U., Javitt D.C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis. Schizophrenia Research 2004, 66(2-3):89-96.
82. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 2005, 57(6):577-585.
83. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 1999, 56(1):29-36.
84. Holscher C., Schmid S., Pilz P.K., Sansig G., van der Putten H., Plappert C.F. Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory. Behavioural Brain Research 2004, 154(2):473-481.
85. Holscher C., Schmid S., Pilz P.K., Sansig G., van der Putten H., Plappert C.F. Lack of the metabotropic glutamate receptor subtype 7 selectively modulates Theta rhythm and working memory. Learning & Memory 2005, 12(5):450-455.
86. Homayoun H., Moghaddam B. Group 5 metabotropic glutamate receptors: Role in modulating cortical activity and relevance to cognition. European Journal of Pharmacology 2010, 639(1-3):33-39.
87. Homayoun H., Stefani M.R., Adams B.W., Tamagan G.D., Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: Effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004, 29(7):1259-1269.
88. Iacovelli L., Arcella A., Battaglia G., Pazzaglia S., Aronica E., Spinsanti P., et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. The Journal of Neuroscience 2006, 26(32):8388-8397.
89. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322(5905):1211-1217.
90. Jacquemont S., Curie A., des Portes V., Torrioli M.G., Berry-Kravis E., Hagerman R.J., et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine 2010, 3(64):64ra61.
91. Javitt D.C., Sershen H., Hashim A., Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997, 17(3):202-204.
92. Jin X., Semenova S., Yang L., Ardecky R., Sheffler D.J., Dahl R., et al. The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology 2010, 35(10):2021-2036.
93. Johnson M.P., Baez M., Jagdmann G.E., Britton T.C., Large T.H., Callagaro D.O., et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: Synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. Journal of Medicinal Chemistry 2003, 46(15):3189-3192.
94. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., et al. Metabotropic glutamate 2 receptor potentiators: Receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 2005, 179(1):271-283.
95. Julio-Pieper M., Flor P.J., Dinan T.G., Cryan J.F. Exciting times beyond the brain: Metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacological Reviews 2011, 63(1):35-38.
96. Kano M., Hashimoto K., Kurihara H., Watanabe M., Inoue Y., Aiba A., et al. Persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking mGluR1. Neuron 1997, 18(1):71-79.
97. Kenakin T. New concepts in drug discovery: Collateral efficacy and permissive antagonism. Nature Reviews. Drug Discovery 2005, 4(11):919-927.
98. Kenakin T. Functional selectivity through protean and biased agonism: Who steers the ship?. Molecular Pharmacology 2007, 72(6):1393-1401.
99. Kew J.N., Pflimlin M.C., Kemp J.A., Mutel V. Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -/- mice. Neuropharmacology 2002, 43(2):215-221.
100. Keywood C., Wakefield M., Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009, 58(9):1192-1199.
101. Kim J.H., Austin J.D., Tanabe L., Creekmore E., Vezina P. Activation of group II mGlu receptors blocks the enhanced drug taking induced by previous exposure to amphetamine. The European Journal of Neuroscience 2005, 21(1):295-300.
102. Kinney G.G., O'Brien J.A., Lemaire W., Burno M., Bickel D.J., Clements M.K., et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. The Journal of Pharmacology and Experimental Therapeutics 2005, 313(1):199-206.
103. Kinoshita A., Shigemoto R., Ohishi H., van der Putten H., Mizuno N. Immunohistochemical localization of metabotropic glutamate receptors, mGluR7a and mGluR7b, in the central nervous system of the adult rat and mouse: A light and electron microscopic study. The Journal of Comparative Neurology 1998, 393(3):332-352.
104. Klak K., Palucha A., Branski P., Sowa M., Pilc A. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 2007, 32(2):169-172.
105. Kniazeff J., Prezeau L., Rondard P., Pin J.P., Goudet C. Dimers and beyond: The functional puzzles of class C GPCRs. Pharmacology & Therapeutics 2011, 130(1):9-25.
106. Knoflach F., Mutel V., Jolidon S., Kew J.N., Malherbe P., Vieira E., et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(23):13402-13407.
107. Kohara A., Toya T., Tamura S., Watabiki T., Nagakura Y., Shitaka Y., et al. Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamid e (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1. The Journal of Pharmacology and Experimental Therapeutics 2005, 315(1):163-169.
108. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews. Drug Discovery 2004, 3(8):711-715.
109. Kolber B.J., Montana M.C., Carrasquillo Y., Xu J., Heinemann S.F., Muglia L.J., et al. Activation of metabotropic glutamate receptor 5 in the amygdala modulates pain-like behavior. The Journal of Neuroscience 2010, 30(24):8203-8213.
110. Kunishima N., Shimada Y., Tsuji Y., Sato T., Yamamoto M., Kumasaka T., et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000, 407(6807):971-977.
111. Langmead C.J., Christopoulos A. Allosteric agonists of 7TM receptors: Expanding the pharmacological toolbox. Trends in Pharmacological Sciences 2006, 27(9):475-481.
112. Lavreysen H., Dautzenberg F.M. Therapeutic potential of group III metabotropic glutamate receptors. Current Medicinal Chemistry 2008, 15(7):671-684.
113. Lavreysen H., Janssen C., Bischoff F., Langlois X., Leysen J.E., Lesage A.S. [3H]R214127: A novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Molecular Pharmacology 2003, 63(5):1082-1093.
114. Leach K., Sexton P.M., Christopoulos A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends in Pharmacological Sciences 2007, 28(8):382-389.
115. Lehmann A. Novel treatments of GERD: Focus on the lower esophageal sphincter. European Review for Medical and Pharmacological Sciences 2008, 12(Suppl. 1):103-110.
116. Li X., Li J., Peng X.Q., Spiller K., Gardner E.L., Xi Z.X. Metabotropic glutamate receptor 7 modulates the rewarding effects of cocaine in rats: Involvement of a ventral pallidal GABAergic mechanism. Neuropsychopharmacology 2009, 34(7):1783-1796.
117. Li X., Need A.B., Baez M., Witkin J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. The Journal of Pharmacology and Experimental Therapeutics 2006, 319(1):254-259.
118. Lindberg J.S., Culleton B., Wong G., Borah M.F., Clark R.V., Shapiro W.B., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. Journal of the American Society of Nephrology 2005, 16(3):800-807.
119. Linden A.M., Baez M., Bergeron M., Schoepp D.D. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: Specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus. Neuropharmacology 2006, 51(2):213-228.
120. Linden A.M., Johnson B.G., Peters S.C., Shannon H.E., Tian M., Wang Y., et al. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 2002, 43(2):251-259.
121. Linden A.M., Shannon H., Baez M., Yu J.L., Koester A., Schoepp D.D. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology (Berl) 2005, 179(1):284-291.
122. Lindsley C.W., Shipe W.D., Wolkenberg S.E., Theberge C.R., Williams D.L., Sur C., et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Current Topics in Medicinal Chemistry 2006, 6(8):771-785.
123. Litschig S., Gasparini F., Rueegg D., Stoehr N., Flor P.J., Vranesic I., et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Molecular Pharmacology 1999, 55(3):453-461.
124. Liu F., Grauer S., Kelley C., Navarra R., Graf R., Zhang G., et al. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: A novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. The Journal of Pharmacology and Experimental Therapeutics 2008, 327(3):827-839.
125. Liu X., He Q., Studholme D.J., Wu Q., Liang S., Yu L. NCD3G: A novel nine-cysteine domain in family 3 GPCRs. Trends in Biochemical Sciences 2004, 29(9):458-461.
126. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117(3):697-706.
127. Lu Y.M., Jia Z., Janus C., Henderson J.T., Gerlai R., Wojtowicz J.M., et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. The Journal of Neuroscience 1997, 17(13):5196-5205.
128. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug; sernyl. Archives of Neurology and Psychiatry 1959, 81(3):363-369.
129. Macek T.A., Winder D.G., Gereau R.W.t., Ladd C.O., Conn P.J. Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses. Journal of Neurophysiology 1996, 76(6):3798-3806.
130. Macinnes N., Duty S. Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo. European Journal of Pharmacology 2008, 580(1-2):95-99.
131. Maj M., Bruno V., Dragic Z., Yamamoto R., Battaglia G., Inderbitzin W., et al. (-)-PHCCC, a positive allosteric modulator of mGluR4: Characterization, mechanism of action, and neuroprotection. Neuropharmacology 2003, 45(7):895-906.
132. Malherbe P., Kratochwil N., Knoflach F., Zenner M.T., Kew J.N., Kratzeisen C., et al. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. The Journal of Biological Chemistry 2003, 278(10):8340-8347.
133. Malherbe P., Kratochwil N., Muhlemann A., Zenner M.T., Fischer C., Stahl M., et al. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. Journal of Neurochemistry 2006, 98(2):601-615.
134. Malherbe P., Kratochwil N., Zenner M.T., Piussi J., Diener C., Kratzeisen C., et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Molecular Pharmacology 2003, 64(4):823-832.
135. Mannaioni G., Marino M.J., Valenti O., Traynelis S.F., Conn P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. The Journal of Neuroscience 2001, 21(16):5925-5934.
136. Marek G.J. Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition. European Journal of Pharmacology 2010, 639(1-3):81-90.
137. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., Aghajanian G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. The Journal of Pharmacology and Experimental Therapeutics 2000, 292(1):76-87.
138. Marino M.J., Conn P.J. Direct and indirect modulation of the N-methyl D-aspartate receptor. Current Drug Targets. CNS and Neurological Disorders 2002, 1(1):1-16.
139. Marino M.J., Williams D.L., O'Brien J.A., Valenti O., McDonald T.P., Clements M.K., et al. Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(23):13668-13673.
140. Masu M., Iwakabe H., Tagawa Y., Miyoshi T., Yamashita M., Fukuda Y., et al. Specific deficit of the ON response in visual transmission by targeted disruption of the mGluR6 gene. Cell 1995, 80(5):757-765.
141. Masugi M., Yokoi M., Shigemoto R., Muguruma K., Watanabe Y., Sansig G., et al. Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion. The Journal of Neuroscience 1999, 19(3):955-963.
142. Mathiesen J.M., Svendsen N., Brauner-Osborne H., Thomsen C., Ramirez M.T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. British Journal of Pharmacology 2003, 138(6):1026-1030.
143. Matsui T., Kita H. Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus. Neuroscience 2003, 122(3):727-737.
144. May L.T., Leach K., Sexton P.M., Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annual Review of Pharmacology and Toxicology 2007, 47:1-51.
145. Miedlich S.U., Gama L., Seuwen K., Wolf R.M., Breitwieser G.E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. The Journal of Biological Chemistry 2004, 279(8):7254-7263.
146. Mitsukawa K., Yamamoto R., Ofner S., Nozulak J., Pescott O., Lukic S., et al. A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(51):18712-18717.
147. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004, 174(1):39-44.
148. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281(5381):1349-1352.
149. Mohler H., Fritschy J.M., Rudolph U. A new benzodiazepine pharmacology. The Journal of Pharmacology and Experimental Therapeutics 2002, 300(1):2-8.
150. Morishima Y., Miyakawa T., Furuyashiki T., Tanaka Y., Mizuma H., Nakanishi S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(11):4170-4175.
151. Moussawi K., Kalivas P.W. Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction. European Journal of Pharmacology 2010, 639(1-3):115-122.
152. Mudo G., Trovato-Salinaro A., Caniglia G., Cheng Q., Condorelli D.F. Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain. Brain Research 2007, 1149:1-13.
153. Muly E.C., Mania I., Guo J.D., Rainnie D.G. Group II metabotropic glutamate receptors in anxiety circuitry: Correspondence of physiological response and subcellular distribution. The Journal of Comparative Neurology 2007, 505(6):682-700.
154. Muto T., Tsuchiya D., Morikawa K., Jingami H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(10):3759-3764.
155. Nakajima Y., Iwakabe H., Akazawa C., Nawa H., Shigemoto R., Mizuno N., et al. Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. The Journal of Biological Chemistry 1993, 268(16):11868-11873.
156. Neugebauer V., Chen P.S., Willis W.D. Role of metabotropic glutamate receptor subtype mGluR1 in brief nociception and central sensitization of primate STT cells. Journal of Neurophysiology 1999, 82(1):272-282.
157. Ngomba R.T., Ferraguti F., Badura A., Citraro R., Santolini I., Battaglia G., et al. Positive allosteric modulation of metabotropic glutamate 4 (mGlu4) receptors enhances spontaneous and evoked absence seizures. Neuropharmacology 2008, 54(2):344-354.
158. Nicholls R.E., Zhang X.L., Bailey C.P., Conklin B.R., Kandel E.R., Stanton P.K. mGluR2 acts through inhibitory Galpha subunits to regulate transmission and long-term plasticity at hippocampal mossy fiber-CA3 synapses. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(16):6380-6385.
159. Nicoletti F., Bruno V., Copani A., Casabona G., Knopfel T. Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders?. Trends in Neurosciences 1996, 19(7):267-271.
160. Niswender C.M. Permissive antagonism induced by negative allosteric modulators of mGluR7. Neuropharmacology 2008, 55:615. (Abstract).
161. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: Physiology, pharmacology, and disease. Annual Review of Pharmacology and Toxicology 2010, 50:295-322.
162. Niswender C.M., Johnson K.A., Miller N.R., Ayala J.E., Luo Q., Williams R., et al. Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Molecular Pharmacology 2010, 77(3):459-468.
163. Niswender C.M., Johnson K.A., Weaver C.D., Jones C.K., Xiang Z., Luo Q., et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Molecular Pharmacology 2008, 74(5):1345-1358.
164. Niswender C.M., Lebois E.P., Luo Q., Kim K., Muchalski H., Yin H., et al. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters 2008, 18(20):5626-5630.
165. O'Brien J.A., Lemaire W., Chen T.B., Chang R.S., Jacobson M.A., Ha S.N., et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Molecular Pharmacology 2003, 64(3):731-740.
166. O'Brien J.A., Lemaire W., Wittmann M., Jacobson M.A., Ha S.N., Wisnoski D.D., et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. The Journal of Pharmacology and Experimental Therapeutics 2004, 309(2):568-577.
167. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study. The Journal of Comparative Neurology 1993, 335(2):252-266.
168. Ott D., Floersheim P., Inderbitzin W., Stoehr N., Francotte E., Lecis G., et al. Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester. Journal of Medicinal Chemistry 2000, 43(23):4428-4436.
169. Pagano A., Ruegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. The Journal of Biological Chemistry 2000, 275(43):33750-33758.
170. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289(5480):739-745.
171. Palucha A., Klak K., Branski P., van der Putten H., Flor P.J., Pilc A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) 2007, 194(4):555-562.
172. Parelkar N.K., Wang J.Q. Upregulation of metabotropic glutamate receptor 8 mRNA expression in the rat forebrain after repeated amphetamine administration. Neuroscience Letters 2008, 433(3):250-254.
173. Parmentier M.L., Prezeau L., Bockaert J., Pin J.P. A model for the functioning of family 3 GPCRs. Trends in Pharmacological Sciences 2002, 23(6):268-274.
174. Patel J.B., Martin C., Malick J.B. Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. European Journal of Pharmacology 1982, 86(2):295-298.
175. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nature Medicine 2007, 13(9):1102-1107.
176. Pecknold J.C., McClure D.J., Appeltauer L., Wrzesinski L., Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. Journal of Clinical Psychopharmacology 1982, 2(2):129-133.
177. Pekhletski R., Gerlai R., Overstreet L.S., Huang X.P., Agopyan N., Slater N.T., et al. Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. The Journal of Neuroscience 1996, 16(20):6364-6373.
178. Peters J., Kalivas P.W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl) 2006, 186(2):143-149.
179. Pin J.P., Galvez T., Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacology & Therapeutics 2003, 98(3):325-354.
180. Pinheiro P.S., Mulle C. Presynaptic glutamate receptors: Physiological functions and mechanisms of action. Nature Reviews. Neuroscience 2008, 9(6):423-436.
181. Pinkerton A.B., Cube R.V., Hutchinson J.H., James J.K., Gardner M.F., Rowe B.A., et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorganic & Medicinal Chemistry Letters 2005, 15(6):1565-1571.
182. Pinkerton A.B., Vernier J.M., Schaffhauser H., Rowe B.A., Campbell U.C., Rodriguez D.E., et al. Phenyl-tetrazolyl acetophenones: Discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor. Journal of Medicinal Chemistry 2004, 47(18):4595-4599.
183. Porter R.H., Jaeschke G., Spooren W., Ballard T.M., Buttelmann B., Kolczewski S., et al. Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. The Journal of Pharmacology and Experimental Therapeutics 2005, 315(2):711-721.
184. Price M.R., Baillie G.L., Thomas A., Stevenson L.A., Easson M., Goodwin R., et al. Allosteric modulation of the cannabinoid CB1 receptor. Molecular Pharmacology 2005, 68(5):1484-1495.
185. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450(7168):383-387.
186. Rodriguez A.L., Grier M.D., Jones C.K., Herman E.J., Kane A.S., Smith R.L., et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Molecular Pharmacology 2010, 78(6):1105-1123.
187. Rodriguez A.L., Nong Y., Sekaran N.K., Alagille D., Tamagnan G.D., Conn P.J. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Molecular Pharmacology 2005, 68(6):1793-1802.
188. Rondard P., Liu J., Huang S., Malhaire F., Vol C., Pinault A., et al. Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors. The Journal of Biological Chemistry 2006, 281(34):24653-24661.
189. Ronesi J.A., Huber K.M. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. The Journal of Neuroscience 2008, 28(2):543-547.
190. Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007, 318(5854):1266-1273.
191. Rosenbrock H., Kramer G., Hobson S., Koros E., Grundl M., Grauert M., et al. Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator. European Journal of Pharmacology 2010, 639(1-3):40-46.
192. Rowe B.A., Schaffhauser H., Morales S., Lubbers L.S., Bonnefous C., Kamenecka T.M., et al. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site. The Journal of Pharmacology and Experimental Therapeutics 2008, 326(1):240-251.
193. Rudd M.T., McCauley J.A. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). Current Topics in Medicinal Chemistry 2005, 5(9):869-884.
194. Sansig G., Bushell T.J., Clarke V.R., Rozov A., Burnashev N., Portet C., et al. Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7. The Journal of Neuroscience 2001, 21(22):8734-8745.
195. Satow A., Maehara S., Ise S., Hikichi H., Fukushima M., Suzuki G., et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: Detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl- N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. The Journal of Pharmacology and Experimental Therapeutics 2008, 326(2):577-586.
196. Schaffhauser H., Rowe B.A., Morales S., Chavez-Noriega L.E., Yin R., Jachec C., et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Molecular Pharmacology 2003, 64(4):798-810.
197. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38(10):1431-1476.
198. Schoepp D.D., Marek G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: Novel agents for schizophrenia?. Current Drug Targets. CNS and Neurological Disorders 2002, 1(2):215-225.
199. Schwartz T.W., Holst B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: Where do they bind and how do they act?. Trends in Pharmacological Sciences 2007, 28(8):366-373.
200. Sheffler D.J., Conn P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells. Neuropharmacology 2008, 55(4):419-427.
201. Shigemoto R., Kinoshita A., Wada E., Nomura S., Ohishi H., Takada M., et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. The Journal of Neuroscience 1997, 17(19):7503-7522.
202. Slassi A., Isaac M., Edwards L., Minidis A., Wensbo D., Mattsson J., et al. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Current Topics in Medicinal Chemistry 2005, 5(9):897-911.
203. Snead O.C., Banerjee P.K., Burnham M., Hampson D. Modulation of absence seizures by the GABA(A) receptor: A critical rolefor metabotropic glutamate receptor 4 (mGluR4). The Journal of Neuroscience 2000, 20(16):6218-6224.
204. Spinelli S., Ballard T., Gatti-McArthur S., Richards G.J., Kapps M., Woltering T., et al. Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology (Berl) 2005, 179(1):292-302.
205. Spooren W., Gasparini F. mGlu5 receptor antagonists: A novel class of anxiolytics?. Drug News & Perspectives 2004, 17(4):251-257.
206. Spooren W.P., Gasparini F., van der Putten H., Koller M., Nakanishi S., Kuhn R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. European Journal of Pharmacology 2000, 397(1):R1-2.
207. Stachowicz K., Branski P., Klak K., van der Putten H., Cryan J.F., Flor P.J., et al. Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. Behavioural Pharmacology 2008, 19(5-6):597-603.
208. Stachowicz K., Chojnacka-Wojcik E., Klak K., Pilc A. Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Pharmacological Reports 2006, 58(6):820-826.
209. Stachowicz K., Klak K., Klodzinska A., Chojnacka-Wojcik E., Pilc A. Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. European Journal of Pharmacology 2004, 498(1-3):153-156.
210. Stefani M.R., Moghaddam B. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. European Journal of Pharmacology 2010, 639(1-3):26-32.
211. Stockton J.M., Birdsall N.J., Burgen A.S., Hulme E.C. Modification of the binding properties of muscarinic receptors by gallamine. Molecular Pharmacology 1983, 23(3):551-557.
212. Sugihara H., Inoue T., Nakanishi S., Fukuda Y. A late ON response remains in visual response of the mGluR6-deficient mouse. Neuroscience Letters 1997, 233(2-3):137-140.
213. Suzuki G., Kawagoe-Takaki H., Inoue T., Kimura T., Hikichi H., Murai T., et al. Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists. Journal of Pharmacological Sciences 2009, 110(3):315-325.
214. Suzuki G., Kimura T., Satow A., Kaneko N., Fukuda J., Hikichi H., et al. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N- methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). The Journal of Pharmacology and Experimental Therapeutics 2007, 321(3):1144-1153.
215. Suzuki G., Tsukamoto N., Fushiki H., Kawagishi A., Nakamura M., Kurihara H., et al. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. The Journal of Pharmacology and Experimental Therapeutics 2007, 323(1):147-156.
216. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Reviews. Drug Discovery 2005, 4(2):131-144.
217. Tamaru Y., Nomura S., Mizuno N., Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites. Neuroscience 2001, 106(3):481-503.
218. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology 2001, 132(7):1423-1430.
219. Thathiah A., De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nature Reviews. Neuroscience 2011, 12(2):73-87.
220. Tong Q., Kirchgessner A.L. Localization and function of metabotropic glutamate receptor 8 in the enteric nervous system. American Journal of Physiology. Gastrointestinal and Liver Physiology 2003, 285(5):G992-G1003.
221. Tong Q., Ouedraogo R., Kirchgessner A.L. Localization and function of group III metabotropic glutamate receptors in rat pancreatic islets. American Journal of Physiology. Endocrinology and Metabolism 2002, 282(6):E1324-E1333.
222. Toyono T., Seta Y., Kataoka S., Harada H., Morotomi T., Kawano S., et al. Expression of the metabotropic glutamate receptor, mGluR4a, in the taste hairs of taste buds in rat gustatory papillae. Archives of Histology and Cytology 2002, 65(1):91-96.
223. Tsuchiya D., Kunishima N., Kamiya N., Jingami H., Morikawa K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(5):2660-2665.
224. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Review of Neurotherapeutics 2009, 9(5):591-598.
225. Uehara S., Muroyama A., Echigo N., Morimoto R., Otsuka M., Yatsushiro S., et al. Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Diabetes 2004, 53(4):998-1006.
226. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., et al. Functional selectivity and classical concepts of quantitative pharmacology. The Journal of Pharmacology and Experimental Therapeutics 2007, 320(1):1-13.
227. Ure J., Baudry M., Perassolo M. Metabotropic glutamate receptors and epilepsy. Journal of the Neurological Sciences 2006, 247(1):1-9.
228. Valenti O., Mannaioni G., Seabrook G.R., Conn P.J., Marino M.J. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. The Journal of Pharmacology and Experimental Therapeutics 2005, 313(3):1296-1304.
229. Valenti O., Marino M.J., Wittmann M., Lis E., DiLella A.G., Kinney G.G., et al. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. The Journal of Neuroscience 2003, 23(18):7218-7226.
230. Vanejevs M., Jatzke C., Renner S., Muller S., Hechenberger M., Bauer T., et al. Positive and negative modulation of group I metabotropic glutamate receptors. Journal of Medicinal Chemistry 2008, 51(3):634-647.
231. Varney M.A., Cosford N.D., Jachec C., Rao S.P., Sacaan A., Lin F.F., et al. SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. The Journal of Pharmacology and Experimental Therapeutics 1999, 290(1):170-181.
232. Varney M.A., Gereau R.W.t. Metabotropic glutamate receptor involvement in models of acute and persistent pain: Prospects for the development of novel analgesics. Current Drug Targets. CNS and Neurological Disorders 2002, 1(3):283-296.
233. Wieronska J.M., Szewczyk B., Branski P., Palucha A., Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002, 23(1-3):213-216.
234. Winquist R.J., Pan J.Q., Gribkoff V.K. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochemical Pharmacology 2005, 70(4):489-499.
235. Woltering T.J., Wichmann J., Goetschi E., Knoflach F., Ballard T.M., Huwyler J., et al. Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorganic & Medicinal Chemistry Letters 2010, 20(23):6969-6974.
236. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196(3):431-440.
237. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330(6007):1066-1071.
238. Xie X., Ramirez D.R., Lasseter H.C., Fuchs R.A. Effects of mGluR1 antagonism in the dorsal hippocampus on drug context-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology (Berl) 2010, 208(1):1-11.
239. Yan Q.J., Rammal M., Tranfaglia M., Bauchwitz R.P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49(7):1053-1066.
240. Yarnitzky T., Levit A., Niv M.Y. Homology modeling of G-protein-coupled receptors with X-ray structures on the rise. Current Opinion in Drug Discovery & Development 2010, 13(3):317-325.
241. Yokoi M., Kobayashi K., Manabe T., Takahashi T., Sakaguchi I., Katsuura G., et al. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 1996, 273(5275):645-647.
242. Zhang Y., Rodriguez A.L., Conn P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. The Journal of Pharmacology and Experimental Therapeutics 2005, 315(3):1212-1219.
243. Zhang G.C., Vu K., Parelkar N.K., Mao L.M., Stanford I.M., Fibuch E.E., et al. Acute administration of cocaine reduces metabotropic glutamate receptor 8 protein expression in the rat striatum in vivo. Neuroscience Letters 2009, 449(3):224-227.